Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is viewed positively because its Pivot to Growth strategy is steadily shifting the business toward higher-margin branded medicines while preserving a resilient generics and biosimilars base. AUSTEDO, UZEDY, and AJOVY are showing strong commercial momentum, and management sees $16.4B-$16.8B of 2026 revenue with net debt/EBITDA at 2.4x, while margin expansion is supported by a richer branded mix and about 300bp of gross margin expansion from 2026-2029. The outlook is further strengthened by a deep pipeline, including duvakitug, LAI olanzapine, ecopipam, and TEV-‘408, which could add meaningful growth and help sustain earnings upside beyond near-term AUSTEDO pricing pressure.

Bears say

Teva Pharmaceutical Indus is viewed negatively because its upside depends on several unproven assumptions across both innovative drugs and the core generics franchise, including duvakitug, AUSTEDO, and the olanzapine LAI launch. Weak Phase 3 outcomes, a restrictive label, slower market growth, or share loss could pressure sales, margins, and cash flow, while the company’s base business also faces headwinds if it fails to double biosimilar revenue by 2027 and recover after the Revlimid impact. In addition, material opioid, price-fixing, and environmental contingencies could derail deleveraging, even as management recently achieved investment grade ratings from Moody’s on August 11, 2026 and from S&P on September 4, 2026.

Teva Pharmaceutical (TEVA) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Buy based on their latest research and market trends.

According to 12 analysts, Teva Pharmaceutical (TEVA) has a Buy consensus rating as of Oct 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.